Skip to main content
JNCI Journal of the National Cancer Institute logoLink to JNCI Journal of the National Cancer Institute
. 2022 Apr 1;115(6):769. doi: 10.1093/jnci/djac065

Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer

PMCID: PMC10248857  PMID: 35362056

Expression of concern to “Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer” by Xiao-Shan Wang et al. JNCI. Journal of the National Cancer Institute, djac015, https://doi.org/10.1093/jnci/djac015

This article was accepted for publication prematurely, before some of the named co-authors had detailed their specific contributions and/or disclosed potential conflicts of interest. In the process of collecting the missing information following article publication, several potential authorship and contributorship issues have been raised. While the journal continues to investigate these matters, readers should note that the author list, as well as the stated disclosures and contributions, may be inaccurate.


Articles from JNCI Journal of the National Cancer Institute are provided here courtesy of Oxford University Press

RESOURCES